# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two addi...
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...
Advanz Pharma secures rights to commercialize Alvotech's biosimilar candidate for Eylea® in Europe Advanz Pharma will le...
- SEC Filing
Under the terms of the agreement, Alvotech will be responsible for development and manufacturing at its state-of-the-art facili...
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...
Barclays analyst Balaji Prasad maintains Alvotech (NASDAQ:ALVO) with a Overweight and raises the price target from $20 to $22.
Alvotech tightened guidance for EBIDTA to $100 - $150 million for the full year.